Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL1408058 | 0.93 | F7 (0.51) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL19057040 | 0.93 | F7 (0.51) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL15699 | 0.91 | F7 (0.56) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL2564207 | 0.91 | F7 (0.56) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL22748483 | 0.91 | F7 (0.56) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL23859925 | 0.90 | F7 (0.55) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL22129922 | 0.90 | F7 (0.55) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL7712105 | 0.90 | F7 (0.55) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL23531099 | 0.90 | F7 (0.55) | SIRT2SIRT1SIRT3F7F3 | |
| Adenine SCHEMBL11807677 | 0.90 | F7 (0.55) | SIRT2SIRT1SIRT3F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | claimed |
| EP-3512486-B1 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2020-10-21 | — | — | EP | claimed |
| EP-3512486-A1 | BLUE POWDER AND USE THEREOF IN COSMETICS | L'Oreal (FR) | 2019-07-24 | — | — | EP | claimed |
| WO-2018050504-A1 | BLUE POWDER AND USE THEREOF IN COSMETICS | L'OREAL (FR) | 2018-03-22 | — | — | WO | claimed |
| US-6750038-B1 | Rapid antibiotic susceptibility test | ESSENTIAL THERAPEUTICS, INC. | 2004-06-15 | — | — | US | claimed |
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| CN-114796107-A | Tobramycin sulfate injection containing nicotinide diphosphate and preparation method thereof | 西藏邦臣药业集团有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3512486-B1 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2020-10-21 | — | — | EP | disclosed |
| CN-110621304-A | Combination of active ingredients, composition comprising the same and use thereof in the treatment of sarcopenia | 阿法玛公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-3512486-A1 | BLUE POWDER AND USE THEREOF IN COSMETICS | L'Oreal (FR) | 2019-07-24 | — | — | EP | disclosed |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-7308363-B2 | Modeling and evaluation metabolic reaction pathways and culturing cells | SRI INTERNATIONAL (US) | 2007-12-11 | — | — | US | disclosed |
| CN-1703422-A | Meth1 and meth2 polynucleotides and polypeptides | HUMAN GENOME SCIENCES INC (US) | 2005-11-30 | — | — | CN | disclosed |
| US-20030154003-A1 | Modeling reaction pathways | SRI INTERNATIONAL | 2003-08-14 | — | — | US | disclosed |
| WO-2003063052-A2 | MODELING REACTION PATHWAYS | SRI INTERNATIONAL, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6153647-A | Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy | MY-TECH, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000027384-A1 | METHOD FOR AUGMENTING THE INOTROPIC EFFECTS OF β-ADRENERGIC AGONISTS USING PYRUVATE THERAPY | MY-TECH, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1995018234-A1 | METHOD FOR ENZYMATICALLY ASSAYING CREATININE OR THE AMMONIUM ION AND REAGENT KIT FOR CARRYING OUT SAID METHOD | PASTEUR SANOFI DIAGNOSTICS (FR) | 1995-07-06 | — | — | WO | disclosed |
| WO-1993003133-A1 | PROCESS FOR THE PRESERVATION OF MICROORGANISM CULTURE MEDIUMS AND PACKAGING UTILIZING THIS PROCESS | NADAUD MICHEL (FR) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | PINK1, PC, PCK2 | SIRT2 1050/4885SIRT1 554/4885SIRT3 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.